**Supplemental Figure S1. Study selection schema.**

Abbreviations: OCCC, ovarian clear cell carcinoma; MOC, mucinous ovarian cancer; LGSOC, low-grade serous ovarian cancer; and HGSOC, high-grade serous ovarian cancer.

Supplemental Table S1. Patient demographics per histology type (early-stage disease, *n*=11750).

Characteristics	HGSOC	OCCC	MOC	LGSOC	*P*-value
Number	n=3269	n=3293	n=4501	n=687	
Age (yr)	60.6 (±13.2)	55.7 (±11.5)	51.2 (±16.4)	55.7 (±14.9)	<0.001
<30	21 (0.6%)	19 (0.6%)	454 (10.1%)	22 (3.2%)	
30-39	141 (4.3%)	204 (6.2%)	624 (13.9%)	74 (10.8%)	
40-49	508 (15.5%)	782 (23.7%)	880 (19.6%)	153 (22.3%)	
50-59	928 (28.4%)	1170 (35.5%)	1119 (24.9%)	163 (23.7%)	
60-69	818 (25.0%)	715 (21.7%)	730 (16.2%)	139 (20.2%)	
70-79	561 (17.2%)	296 (9.0%)	483 (10.7%)	94 (13.7%)	
≥80	292 (8.9%)	107 (3.2%)	211 (4.7%)	42 (6.1%)	
Year					<0.001
1988-1993	263 (8.8%)	241 (8.0%)	608 (14.9%)	107 (17.1%)	
1994-1999	405 (13.6%)	347 (11.6%)	616 (15.0%)	117 (18.7%)	
2000-2005	757 (25.4%)	742 (24.7%)	952 (23.3%)	166 (26.5%)	
2006-2011	839 (28.2%)	849 (28.3%)	960 (23.4%)	135 (21.6%)	
2012-2016	715 (24.0%)	824 (27.4%)	958 (23.4%)	101 (16.1%)	
Race/ethnicity					<0.001
White	2521 (77.1%)	2296 (69.7%)	3192 (70.9%)	518 (75.4%)	
Black	179 (5.5%)	93 (2.8%)	264 (5.9%)	45 (6.6%)	
Hispanic	304 (9.3%)	306 (9.3%)	508 (11.3%)	78 (11.4%)	
Asian	227 (6.9%)	537 (16.3%)	440 (9.8%)	37 (5.4%)	
Others*	38 (1.2%)	61 (1.9%)	97 (2.2%)	9 (1.3%)	
Registry					<0.001
West	1742 (53.3%)	1991 (60.5%)	2428 (53.9%)	336 (48.9%)	
Central	751 (23.0%)	537 (16.3%)	1014 (22.5%)	150 (21.8%)	
East	776 (23.7%)	765 (23.2%)	1059 (23.5%)	201 (29.3%)	
Marital status					<0.001
Single	526 (16.1%)	762 (23.1%)	1113 (24.7%)	132 (19.2%)	
Married	1805 (55.2%)	1834 (55.7%)	2238 (49.7%)	389 (56.6%)	
Others	101 (3.1%)	120 (3.6%)	170 (3.8%)	17 (2.5%)	
Unknown	837 (25.6%)	577 (17.5%)	980 (21.8%)	149 (21.7%)	
Stage					<0.001
IA	1326 (40.6%)	1874 (56.9%)	3212 (71.4%)	365 (53.1%)	
IB	303 (9.3%)	71 (2.2%)	105 (2.3%)	61 (8.9%)	
IC	1553 (47.5%)	1267 (38.5%)	1049 (23.3%)	233 (33.9%)	
INOS	87 (2.7%)	81 (2.5%)	135 (3.0%)	28 (4.1%)	
Tumor size (cm)					<0.001
<5	669 (20.5%)	506 (15.4%)	705 (15.7%)	160 (23.3%)	
5-9.9	674 (20.6%)	629 (19.1%)	386 (8.6%)	129 (18.8%)	
10-14.9	557 (17.0%)	657 (20.0%)	473 (10.5%)	70 (10.2%)	
≥15	485 (14.8%)	813 (24.7%)	1555 (34.5%)	76 (11.1%)	
Unknown	884 (27.0%)	688 (20.9%)	1382 (30.7%)	252 (36.7%)	
Oophorectomy					0.019
No	26 (0.8%)	10 (0.3%)	36 (0.8%)	5 (0.7%)	
Yes	3232 (98.9%)	3281 (99.6%)	4455 (99.0%)	681 (99.1%)	
NOS*	11 (0.3%)	2 (0.1%)	10 (0.2%)	1 (0.1%)	
Hysterectomy					<0.001
No	649 (19.9%)	395 (12.0%)	1214 (27.0%)	139 (20.2%)	
Yes	2501 (76.5%)	2789 (84.7%)	3079 (68.4%)	524 (76.3%)	

Unknown	119 (3.6%)	109 (3.3%)	208 (4.6%)	24 (3.5%)	
Lymphadenectomy					<0.001
No	1192 (36.5%)	826 (25.1%)	1887 (41.9%)	323 (47.0%)	
Yes	2069 (63.3%)	2463 (74.8%)	2601 (57.8%)	361 (52.5%)	
Unknown	8 (0.2%)	4 (0.1%)	13 (0.3%)	3 (0.4%)	
Sampled nodes**	12 (IQR 6-20)	13 (IQR 6-21)	10 (IQR 5-18)	9 (IQR 4.5-19)	<0.001
Chemotherapy					<0.001
No	1275 (]39.0%)	1045 (31.7%)	3244 (72.1%)	494 (71.9%)	
Yes	1994 (61.0%)	2248 (68.3%)	1257 (27.9%)	193 (28.1%)	

Number (percentage per column), mean (±standard deviation), or median (interquartile range) is shown. One-way ANOVA test, Kruskal-Wallis *H* test, or chi-square test for *P*-values. *including unknown. **among staged cases. Abbreviations: IQR, interquartile range; NOS, not otherwise specified; HGSOC, high-grade serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma; MOC, mucinous ovarian carcinoma; and LGSOC, low-grade serous ovarian carcinoma.

Supplemental Table S2. Patient demographics per histology type (advanced-stage disease, *n*=37399).

Characteristics	HGSOC	OCCC	MOC	LGSOC	*P*-value
Number	*n*=31874	*n*=1842	*n*=2568	*n*=1115	
Age	63.0 (±12.1)	58.2 (±12.3)	62.4 (±15.3)	55.7 (±12.7)	<0.001
<30	132 (0.4%)	5 (0.3%)	57 (2.2%)	73 (6.5%)	
30-39	727 (2.3%)	101 (5.5%)	134 (5.2%)	125 (11.2%)	
40-49	3797 (11.9%)	351 (19.1%)	344 (13.4%)	201 (18.0%)	
50-59	7723 (24.2%)	570 (30.9%)	550 (21.4%)	240 (21.5%)	
60-69	9380 (29.4%)	474 (25.7%)	559 (21.8%)	232 (20.8%)	
70-79	7373 (23.1%)	257 (14.0%)	562 (21.9%)	165 (14.8%)	
≥80	2742 (8.6%)	84 (4.6%)	362 (14.1%)	79 (7.1%)	
Year					<0.001
1988-1993	2477 (8.5%)	140 (8.5%)	383 (16.2%)	133 (13.0%)	
1994-1999	3652 (12.6%)	184 (11.1%)	453 (19.2%)	171 (16.7%)	
2000-2005	7869 (27.1%)	459 (27.8%)	747 (31.7%)	336 (32.7%)	
2006-2011	8206 (27.1%)	479 (29.0%)	481 (20.4%)	223 (21.7%)	
2012-2016	6837 (23.5%)	392 (23.7%)	296 (12.5%)	164 (16.0%)	
Race/ethnicity					<0.001
White	24722 (77.6%)	1304 (70.8%)	1761 (68.6%)	868 (77.8%)	
Black	2000 (6.3%)	106 (5.8%)	309 (12.0%)	81 (7.3%)	
Hispanic	2946 (9.2%)	159 (8.6%)	299 (11.6%)	116 (10.4%)	
Asian	1807 (5.7%)	248 (13.5%)	158 (6.2%)	37 (3.3%)	
Others*	399 (1.3%)	25 (1.4%)	41 (1.6%)	13 (1.2%)	
Registry area					<0.001
West	18121 (56.9%)	1097 (59.6%)	1366 (53.2%)	604 (54.2%)	
Central	5906 (18.5%)	324 (17.6%)	583 (22.7%)	228 (20.4%)	
East	7847 (24.6%)	421 (22.9%)	619 (24.1%)	283 (25.4%)	
Marital status					<0.001
Single	4160 (13.1%)	422 (22.9%)	489 (19.0%)	216 (19.4%)	
Married	17550 (55.1%)	974 (52.9%)	1134 (44.2%)	598 (53.6%)	
Others	940 (2.9%)	59 (3.2%)	76 (3.0%)	24 (2.2%)	
Unknown	9224 (28.9%)	387 (21.0%)	869 (33.8%)	277 (24.8%)	
Stage					<0.001
III	20916 (65.6%)	1237 (67.2%)	1395 (54.3%)	861 (77.2%)	
IV	10958 (34.4%)	605 (32.8%)	1173 (45.7%)	254 (22.8%)	
Nodal metastasis					<0.001
No	5191 (16.3%)	423 (23.0%)	389 (15.1%)	231 (20.7%)	
Yes	8793 (27.6%)	607 (33.0%)	330 (12.9%)	326 (29.2%)	
Unstaged	17890 (56.1%)	812 (44.1%)	1849 (72.0%)	558 (50.0%)	
LNR**	50 (IQR 18-100)	33 (IQR 13-69)	33 (IQR 13-100)	29 (IQR 14-67)	<0.001
Tumor size (cm)					<0.001
<5	5043 (15.8%)	155 (8.4%)	173 (6.7%)	184 (16.5%)	
5-9.9	7164 (22.5%)	321 (17.4%)	269 (10.5%)	234 (21.0%)	
10-14.9	4299 (13.5%)	383 (20.8%)	265 (10.3%)	128 (11.5%)	
≥15	2314 (7.3%)	422 (22.9%)	464 (18.1%)	106 (9.5%)	
Unknown	13054 (41.0%)	561 (30.5%)	1397 (54.4%)	463 (41.5%)	
Oophorectomy					<0.001
No	1640 (5.1%)	148 (8.0%)	684 (26.6%)	56 (5.0%)	
Yes	29999 (94.1%)	1682 (91.3%)	1830 (71.3%)	1049 (94.1%)	
NOS*	235 (0.7%)	12 (0.7%)	54 (2.1%)	10 (0.9%)	

Hysterectomy					<0.001
No	4192 (13.2%)	255 (13.8%)	983 (38.3%)	196 (17.6%)	
Yes	24741 (77.6%)	1455 (79.0%)	1313 (51.1%)	785 (70.4%)	
Unknown	2941 (9.2%)	132 (7.2%)	272 (10.6%)	134 (12.0%)	
Lymphadenectomy					<0.001
No	17737 (55.6%)	796 (43.2%)	1802 (70.2%)	552 (49.5%)	
Yes	13934 (43.7%)	1028 (55.8%)	721 (28.1%)	556 (49.9%)	
Unknown	203 (0.6%)	18 (1.0%)	45 (1.8%)	7 (0.6%)	
Sampled nodes**	10 (IQR 3-23)	12 (IQR 4-23)	9 (IQR 3-25)	11 (IQR 5-23)	0.004
Chemotherapy					<0.001
No	5350 (16.8%)	368 (20.0%)	944 (36.8%)	255 (22.9%)	
Yes	26524 (83.2%)	1474 (80.0%)	1624 (63.2%)	860 (77.1%)	

Number (percentage per column), mean (±standard deviation), or median (interquartile range) is shown. One-way ANOVA test, Kruskal-Wallis *H* test, or chi-square test for *P*-values. *including unknown. **among staged cases. Abbreviations: IQR, interquartile range; NOS, not otherwise specified; LNR, lymph node ratio; HGSOC, high-grade serous ovarian carcinoma; OCCC, ovarian clear cell carcinoma; MOC, mucinous ovarian carcinoma; and LGSOC, low-grade serous ovarian carcinoma.

Supplemental Table S3. Demographics after propensity score match for OCCC *versus* HGSOC (early stage).

Characteristics	HGSOC	OCCC	*SD*
Number	*n*=2368	*n*=2368	
Age	57.8 (±12.4)	57.6 (±11.7)	0.01
Year			<0.01
1988-1993	182 (8.8%)	186 (9.0%)	
1994-1999	268 (12.9%)	262 (12.6%)	
2000-2005	518 (24.9%)	527 (25.4%)	
2006-2011	597 (28.7%)	578 (27.8%)	
2012-2016	513 (24.7%)	525 (25.3%)	
Race/ethnicity			0.01
White	1796 (75.8%)	1788 (75.5%)	
Black	90 (3.8%)	81 (3.4%)	
Hispanic	236 (10.0%)	239 (10.1%)	
Asian	210 (8.9%)	228 (9.6%)	
Others	36 (1.5%)	32 (1.4%)	
Registry			0.03
West	1298 (54.8%)	1344 (56.8%)	
Central	491 (20.7%)	452 (19.1%)	
East	579 (24.5%)	572 (24.2%)	
Marital status			0.01
Single	450 (19.0%)	458 (19.3%)	
Married	1360 (57.4%)	1332 (56.3%)	
Others	77 (3.3%)	80 (3.4%)	
Unknown	481 (20.3%)	498 (21.0%)	
Stage			0.06
IA	1128 (47.6%)	1207 (51.0%)	
IB	95 (4.0%)	70 (3.0%)	
IC	1080 (45.6%)	1026 (43.3%)	
INOS	65 (2.7%)	65 (2.7%)	
Tumor size (cm)			<0.01
<5	414 (17.5%)	408 (17.2%)	
5-9.9	479 (20.2%)	465 (19.6%)	
10-14.9	453 (19.1%)	459 (19.4%)	
≥15	423 (17.9%)	470 (19.8%)	
Unknown	599 (25.3%)	566 (23.9%)	
Oophorectomy			<0.01
No	10 (0.4%)	8 (0.3%)	
Yes	2358 (99.6%)	2358 (99.6%)	
NOS	0	2 (0.1%)	
Hysterectomy			<0.01
No	333 (14.1%)	341 (14.4%)	
Yes	1953 (82.5%)	1942 (82.0%)	
Unknown	82 (3.5%)	85 (3.6%)	
Lymphadenectomy			0.03
No	720 (30.4%)	689 (29.1%)	
Yes	1643 (69.4%)	1676 (70.8%)	
Unknown	5 (0.2%)	3 (0.1%)	
Chemotherapy			0.02
No	848 (35.8%)	821 (34.7%)	

Yes	1520 (64.2%)	1547 (65.3%)

Abbreviations: HGSOC, high-grade serous ovarian cancer; OCCC, ovarian clear cell carcinoma; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.

Supplemental Table S4. Demographics after propensity score match for MOC *versus* HGSOC (early stage).

Characteristics	HGSOC	MOC	*SD*
Number	*n*=2176	*n*=2176	
Age	58.4 (±13.3)	57.3 (±15.6)	0.08
Year			<0.01
1988-1993	212 (11.2%)	212 (11.2%)	
1994-1999	290 (15.4%)	295 (15.6%)	
2000-2005	479 (25.4%)	488 (25.9%)	
2006-2011	486 (25.8%)	473 (25.1%)	
2012-2016	419 (22.2%)	418 (22.2%)	
Race/ethnicity			0.01
White	1631 (75.0%)	1621 (74.5%)	
Black	127 (5.8%)	124 (5.7%)	
Hispanic	213 (9.8%)	222 (10.2%)	
Asian	172 (7.9%)	177 (8.1%)	
Others	33 (1.5%)	32 (1.5%)	
Registry			<0.01
West	1141 (52.4%)	1147 (52.7%)	
Central	522 (24.0%)	497 (22.8%)	
East	513 (23.6%)	532 (24.4%)	
Marital status			0.03
Single	405 (18.6%)	441 (20.3%)	
Married	1151 (52.9%)	1124 (51.7%)	
Others	69 (3.2%)	76 (3.5%)	
Unknown	551 (25.3%)	535 (24.6%)	
Stage			0.10
IA	1107 (50.9%)	1237 (56.8%)	
IB	119 (5.5%)	86 (4.0%)	
IC	879 (40.4%)	787 (36.2%)	
INOS	71 (3.3%)	66 (3.0%)	
Tumor size (cm)			0.03
<5	408 (18.8%)	406 (18.7%)	
5-9.9	306 (14.1%)	277 (12.7%)	
10-14.9	360 (16.5%)	310 (14.2%)	
≥15	437 (20.1%)	520 (23.9%)	
Unknown	665 (30.6%)	663 (30.5%)	
Oophorectomy			0.01
No	23 (1.1%)	14 (0.6%)	
Yes	2146 (98.6%)	2154 (99.0%)	
NOS	7 (0.3%)	8 (0.4%)	
Hysterectomy			0.01
No	456 (21.0%)	464 (21.3%)	
Yes	1639 (75.3%)	1608 (73.9%)	
Unknown	81 (3.7%)	104 (4.8%)	
Lymphadenectomy			0.03
No	847 (38.9%)	882 (40.5%)	
Yes	1324 (60.8%)	1287 (59.1%)	
Unknown	5 (0.2%)	7 (0.3%)	
Chemotherapy			0.09
No	1098 (50.5%)	1194 (54.9%)	

Yes	1078 (49.5%)	982 (45.1%)

Abbreviations: HGSOC, high-grade serous ovarian cancer; MOC, mucinous ovarian carcinoma; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.

Supplemental Table S5. Demographics after propensity score match for LGSOC *versus* HGSOC (early stage).

Characteristics	HGSOC	LGSOC	*SD*
Number	*n*=671	*n*=671	
Age	57.4 (±13.7)	56.1 (±14.8)	0.09
Year			<0.01
1988-1993	90 (14.8%)	95 (15.6%)	
1994-1999	116 (19.0%)	114 (18.7%)	
2000-2005	176 (28.9%)	165 (27.0%)	
2006-2011	133 (21.8%)	135 (22.1%)	
2012-2016	95 (15.6%)	101 (16.6%)	
Race/ethnicity			0.03
White	517 (77.0%)	505 (75.3%)	
Black	38 (5.7%)	44 (6.6%)	
Hispanic	72 (10.7%)	77 (11.5%)	
Asian	37 (5.5%)	37 (5.5%)	
Others	7 (1.0%)	8 (1.2%)	
Registry			0.03
West	341 (50.8%)	330 (49.2%)	
Central	139 (20.7%)	145 (21.6%)	
East	191 (28.5%)	196 (29.2%)	
Marital status			0.03
Single	125 (18.6%)	129 (19.2%)	
Married	373 (55.6%)	376 (56.0%)	
Others	15 (2.2%)	17 (2.5%)	
Unknown	158 (23.5%)	149 (22.2%)	
Stage			0.03
IA	344 (51.3%)	354 (52.8%)	
IB	57 (8.5%)	60 (8.9%)	
IC	243 (36.2%)	230 (34.3%)	
INOS	27 (4.0%)	27 (4.0%)	
Tumor size (cm)			0.01
<5	160 (23.8%)	157 (23.4%)	
5-9.9	134 (20.0%)	128 (19.1%)	
10-14.9	69 (10.3%)	70 (10.4%)	
≥15	62 (9.2%)	75 (11.2%)	
Unknown	246 (36.7%)	241 (35.9%)	
Oophorectomy			<0.01
No	5 (0.7%)	5 (0.7%)	
Yes	665 (99.1%)	665 (99.1%)	
NOS*	1 (0.1%)	1 (0.1%)	
Hysterectomy			<0.01
No	136 (20.3%)	136 (20.3%)	
Yes	512 (76.3%)	511 (76.2%)	
Unknown	23 (3.4%)	24 (3.6%)	
Lymphadenectomy			0.04
No	320 (47.7%)	307 (45.8%)	
Yes	347 (51.7%)	361 (53.8%)	
Unknown	4 (0.6%)	3 (0.4%)	
Chemotherapy			0.07
No	458 (68.3%)	478 (71.2%)	

Yes	213 (31.7%)	193 (28.8%)

Abbreviations: HGSOC, high-grade serous ovarian cancer; LGSOC, low-grade serous ovarian cancer; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.

Supplemental Table S6. Demographics after propensity score match for OCCC *versus* HGSOC (advanced stage).

Characteristics	HGSOC	OCCC	*SD*
Number	*n*=1834	*n*=1834	
Age	58.4 (±13.1)	58.3 (±12.3)	<0.01
Year			
1988-1993	144 (8.7%)	140 (8.5%)	
1994-1999	194 (11.8%)	183 (11.1%)	
2000-2005	481 (29.2%)	457 (27.8%)	
2006-2011	469 (28.5%)	475 (28.9%)	
2012-2016	358 (21.7%)	391 (23.8%)	
Race/ethnicity			0.05
White	1337 (72.9%)	1304 (71.1%)	
Black	115 (6.3%)	106 (5.8%)	
Hispanic	152 (8.3%)	159 (8.7%)	
Asian	205 (11.2%)	240 (13.1%)	
Others	25 (1.4%)	25 (1.4%)	
Registry			0.01
West	1077 (58.7%)	1090 (59.4%)	
Central	330 (18.0%)	324 (17.7%)	
East	427 (23.3%)	420 (22.9%)	
Marital status			0.02
Single	401 (21.9%)	417 (22.7%)	
Married	981 (53.5%)	971 (52.9%)	
Others	56 (3.1%)	59 (3.2%)	
Unknown	396 (21.6%)	387 (21.1%)	
Stage			0.06
III	1179 (64.3%)	1232 (67.2%)	
IV	655 (35.7%)	602 (32.8%)	
Tumor size (cm)			<0.01
<5	170 (9.3%)	155 (8.5%)	
5-9.9	342 (18.6%)	321 (17.5%)	
10-14.9	345 (18.8%)	383 (20.9%)	
≥15	377 (20.6%)	414 (22.6%)	
Unknown	600 (32.7%)	561 (30.6%)	
Oophorectomy			0.03
No	132 (7.2%)	148 (8.1%)	
Yes	1691 (92.2%)	1674 (91.3%)	
NOS	11 (0.6%)	12 (0.7%)	
Hysterectomy			0.03
No	240 (13.1%)	253 (13.8%)	
Yes	1453 (79.2%)	1449 (79.0%)	
Unknown	141 (7.7%)	132 (7.2%)	
Lymphadenectomy			0.02
No	822 (44.8%)	794 (43.3%)	
Yes	988 (53.9%)	1022 (55.7%)	
Unknown	24 (1.3%)	18 (1.0%)	
Chemotherapy			0.02
No	378 (20.6%)	365 (19.9%)	
Yes	1456 (79.4%)	1469 (80.1%)	

Abbreviations: HGSOC, high-grade serous ovarian cancer; OCCC, ovarian clear cell carcinoma; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.

Supplemental Table S7. Demographics after propensity score match for MOC *versus* HGSOC (advanced stage).

Characteristics	HGSOC	MOC	SD
Number	*n*=2557	*n*=2557	
Age	62.5 (±13.2)	62.4 (±15.3)	<0.01
Year			0.03
1988-1993	367 (15.6%)	381 (16.2%)	
1994-1999	481 (20.5%)	449 (19.1%)	
2000-2005	770 (32.8%)	743 (31.6%)	
2006-2011	477 (20.3%)	480 (20.4%)	
2012-2016	254 (10.8%)	296 (12.6%)	
Race/ethnicity			<0.01
White	1785 (69.8%)	1757 (68.7%)	
Black	266 (10.4%)	304 (11.9%)	
Hispanic	301 (11.8%)	299 (11.7%)	
Asian	172 (6.7%)	158 (6.2%)	
Others	33 (1.3%)	39 (1.5%)	
Registry			0.02
West	1331 (52.1%)	1362 (53.3%)	
Central	595 (23.3%)	577 (22.6%)	
East	631 (24.7%)	618 (24.2%)	
Marital status			<0.01
Single	464 (18.1%)	481 (18.8%)	
Married	1168 (45.7%)	1133 (44.3%)	
Others	65 (2.5%)	75 (2.9%)	
Unknown	860 (33.6%)	868 (33.9%)	
Stage			0.02
III	1424 (55.7%)	1394 (54.5%)	
IV	1133 (44.3%)	1163 (45.5%)	
Tumor size (cm)			<0.01
<5	173 (6.8%)	173 (6.8%)	
5-9.9	263 (10.3%)	269 (10.5%)	
10-14.9	292 (11.4%)	265 (10.4%)	
≥15	432 (16.9%)	461 (18.0%)	
Unknown	1397 (54.6%)	1389 (54.3%)	
Oophorectomy			0.06
No	604 (23.6%)	673 (26.3%)	
Yes	1902 (74.4%)	1830 (71.6%)	
NOS*	51 (2.0%)	54 (2.1%)	
Hysterectomy			0.07
No	887 (34.7%)	972 (38.0%)	
Yes	1371 (53.6%)	1313 (51.3%)	
Unknown	299 (11.7%)	272 (10.6%)	
Lymphadenectomy			<0.01
No	1787 (69.9%)	1794 (70.2%)	
Yes	740 (28.9%)	721 (28.2%)	
Unknown	30 (1.2%)	42 (1.6%)	
Chemotherapy			0.05
No	878 (34.3%)	934 (36.5%)	
Yes	1679 (65.7%)	1623 (63.5%)	

Abbreviations: HGSOC, high-grade serous ovarian cancer; MOC, mucinous ovarian carcinoma; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.

Supplemental Table S8. Demographics after propensity score match for LGSOC *versus* HGSOC (advanced stage).

Characteristics	HGSOC	OCCC	*SD*
Number	*n*=1095	*n*=1095	
Age	56.8 (±13.5)	56.3 (±15.8)	0.03
Year			<0.01
1988-1993	134 (13.3%)	128 (12.7%)	
1994-1999	167 (16.6%)	170 (16.9%)	
2000-2005	316 (31.4%)	327 (32.5%)	
2006-2011	240 (23.8%)	221 (21.9%)	
2012-2016	150 (14.9%)	161 (16.0%)	
Race/ethnicity			0.02
White	850 (77.6%)	857 (78.3%)	
Black	80 (7.3%)	78 (7.1%)	
Hispanic	109 (10.0%)	110 (10.0%)	
Asian	44 (4.0%)	37 (3.4%)	
Others*	12 (1.1%)	13 (1.2%)	
Registry			<0.01
West	600 (54.8%)	593 (54.2%)	
Central	214 (19.5%)	225 (20.5%)	
East	281 (25.7%)	277 (25.3%)	
Marital status			0.03
Single	192 (17.5%)	204 (18.6%)	
Married	622 (56.8%)	591 (54.0%)	
Others	28 (2.6%)	23 (2.1%)	
Unknown	253 (23.1%)	277 (25.3%)	
Stage			0.08
III	803 (73.3%)	841 (76.8%)	
IV	292 (26.7%)	254 (23.2%)	
Tumor size (cm)			0.03
<5	171 (15.6%)	181 (16.5%)	
5-9.9	222 (20.3%)	228 (20.8%)	
10-14.9	129 (11.8%)	127 (11.6%)	
≥15	110 (10.0%)	100 (9.1%)	
Unknown	463 (42.3%)	459 (41.9%)	
Oophorectomy			0.05
No	68 (6.2%)	56 (5.1%)	
Yes	1018 (93.0%)	1029 (94.0%)	
NOS*	9 (0.8%)	10 (0.9%)	
Hysterectomy			0.06
No	216 (19.7%)	181 (16.5%)	
Yes	750 (68.5%)	783 (71.5%)	
Unknown	129 (11.8%)	131 (12.0%)	
Lymphadenectomy			0.02
No	557 (50.9%)	548 (50.0%)	
Yes	531 (48.5%)	540 (49.3%)	
Unknown	7 (0.6%)	7 (0.6%)	
Chemotherapy			0.03
No	234 (21.4%)	248 (22.6%)	
Yes	861 (78.6%)	847 (77.4%)	

Abbreviations: HGSOC, high-grade serous ovarian cancer; LGSOC, low-grade serous ovarian cancer; SD, standardized difference; and NOS, not otherwise specified. SD ≤0.10 indicates good balance between the two groups.